Fig. 4: B-LNP/diABZI treatment reprograms metabolic features of TAMC. | Nature Communications

Fig. 4: B-LNP/diABZI treatment reprograms metabolic features of TAMC.

From: STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma

Fig. 4: B-LNP/diABZI treatment reprograms metabolic features of TAMC.The alt text for this image may have been generated using AI.

Bulk metabolomic analysis of TAMCs from CT-2A-bearing brains of C57 mice received radiotherapy (RT) or RT + B-LNP/diABZI combination therapy (referred to as Combo). Unbiased metabolomics (a) and metabolic pathway analysis (b) of TAMCs from brain tumors. c Schematic illustration of the arginine metabolic pathway. LC-MS/MS analysis of iNOS (d), ARG1 (e), and ornithine decarboxylase (ODC) (f)-derived metabolites in TAMCs. n = 3 samples (TAMCs collected from 5 CT-2A-bearing mice were pooled for each sample; in total, 15 mice per treatment group). Statistics were determined by two-sided Student’s t-test. The data are presented as mean + /- SEM. Source data are provided as a Source Data file.

Back to article page